The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $17.11

Today's change-0.11 -0.64%
Updated July 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $17.11

Today's change-0.11 -0.64%
Updated July 24 4:00 PM EDT. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc down (U.S.)$0.11

Ironwood Pharmaceuticals Inc closed lower Monday, dropping (U.S.)$0.11 or 0.64% to (U.S.)$17.11. Shares have lost 9.90% over the last five days, but have gained 11.90% over the last year to date. This security has outperformed the S&P 500 by 6.34% during the last year.

Key company metrics

  • Open(U.S.) $17.14
  • Previous close(U.S.) $17.22
  • High(U.S.) $17.37
  • Low(U.S.) $16.81
  • Bid / Ask(U.S.) $16.19 / (U.S.) $17.25
  • YTD % change+11.90%
  • Volume907,347
  • Average volume (10-day)1,287,141
  • Average volume (1-month)1,125,537
  • Average volume (3-month)1,234,674
  • 52-week range(U.S.) $12.48 to (U.S.) $19.94
  • Beta1.42
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.83
Updated July 24 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.36%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue52876654
Total other revenue--------
Total revenue52876654
Gross profit52866654
Total cost of revenue1200
Total operating expense94949470
Selling / general / administrative56554537
Research & development34383832
Depreciation / amortization0--31
Interest expense (income), net operating--------
Unusual expense (income)2000
Other operating expenses, total2-29--
Operating income-42-6-28-15
Interest income (expense), net non-operating-9-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-53-14-33-22
Income after tax-53-14-33-22
Income tax, total--------
Net income-53-14-33-22
Total adjustments to net income--------
Net income before extra. items-53-14-33-22
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-53-14-33-22
Inc. avail. to common incl. extra. items-53-14-33-22
Diluted net income-53-14-33-22
Dilution adjustment--------
Diluted weighted average shares148146145145
Diluted EPS excluding extraordinary itemsvalue per share-0.36-0.09-0.23-0.15
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.34-0.09-0.23-0.15